Hematologic Oncology | Specialty

New Study Demonstrates Advances in Creating Treatment for Common Childhood Blood Cancer

October 31st 2014

Researchers at NYU Langone Medical Center conclude new drug in development may offer first alternative to standard chemotherapy for T-Cell Acute Lymphoblastic Leukemia

Blood Cancer-Related Mutations Commonly Found in Older Individuals

October 28th 2014

Mutations known to be involved in hematologic malignancies were found in the blood cells of 2%-3% of individuals over age 40 and 5%-6% of those over age 70.

Latest News & Insight: October 27, 2014

October 27th 2014

CAR Therapy Demonstrates Promise in ALL

October 17th 2014

The investigational chimeric antigen receptor (CAR) therapy CTL019 demonstrated promising activity in 2 pilot trials, eliciting complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL).

Dr. Emerson Explains the Connection Between Stem Cell Mutations and Leukemia

October 16th 2014

Stephen G Emerson, MD, PhD, Clyde Wu Professor of Immunology and Medicine, director, Herbert Irving Comprehensive Cancer Center, explains the connection between stem cell mutations and leukemia.

FDA Grants Priority Review to Blinatumomab in Adult ALL

October 9th 2014

The FDA has assigned a priority review designation to blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

Ibrutinib, ABT-199 Combo Effective in MCL and CLL

September 24th 2014

The combination of ABT-199 and ibrutinib (Imbruvica) demonstrated promising early activity in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) cell lines

Infinity Inks Deals to Expand Research Into Duvelisib

September 23rd 2014

Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.

Amgen Seeks FDA Approval for Blinatumomab in ALL

September 22nd 2014

A Biologics License Application has been submitted to the FDA for the bispecific T-cell engager (BiTE) antibody blinatumomab as a treatment for adult patients with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)

Novel Treatment Strategy Could Overcome Resistance

September 22nd 2014

A preclinical study has shown promising steps toward tackling drug resistance in hematologic malignancies using sequential dosing of drugs targeted against vulnerabilities that emerge as a result of tumor evolution

Novel Therapies on the Horizon in AML

September 18th 2014

Treatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care.

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

September 18th 2014

Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial.

Radiation Therapy Improves Survival in Hodgkin's Lymphoma

September 15th 2014

Despite a recent decline in utilization, consolidated radiation therapy has been shown to improve 10-year survival rates for patients with stage I/II Hodgkin's lymphoma following treatment with chemotherapy

Dr. Pardee on CPI-613 for Patients With R/R AML

September 11th 2014

Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Rosenberg Sees New Milestone in Latest CAR Findings

September 9th 2014

Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.

Alpha-Particle Radiopharmaceuticals Moving Forward as AML Therapy

September 8th 2014

Although standard induction therapy produces complete remissions in 50% to 70% of patients with acute myeloid leukemia (AML), long-term survival is seen in only 20% to 40% of patients. The prognosis for older patients is even worse, with a 5-year survival rate of 5% for patients older than 65 years.

Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy for Leukemia and Beyond

August 29th 2014

Chimeric antigen receptor T-cell therapy is an immunotherapy in which the patient's own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient.

Dr. Younes on Brentuximab Plus AVD vs ABVD in Classical Hodgkin Lymphoma

August 28th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the ongoing Echelon-1 study in classical Hodgkin lymphoma.

Dr. Sawyer on LBM Outcomes With Siltuximab in Multicentric Castleman's Disease

August 26th 2014

Michael Sawyer, MD, associate professor, Medical Oncology, University of Alberta, discusses lean body mass (LBM) outcomes in patients with multicentric Castleman's disease who received siltuximab (Sylvant).

Dr. Flinn Discusses IPI-145 as Potential Treatment for Hematologic Malignancies

August 26th 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.